Filing Flows › Journey Medical (DERM) › Q2 2026 › vs Q2 2025
Journey Medical (DERM) Q2 2026 vs Q2 2025 (year over year)
Journey Medical's revenue rose $3.5M (+23%) from $15.0M in Q2 2025 to $18.5M in Q2 2026. The biggest changes: Emrosi +$5.3M (+189%); Qbrexza −$1.8M (-26%); Other / legacy −$503K (-68%).
Journey Medical, Q2 2026: revenue $18.5M (+23% year over year), operating margin 2.5%, net loss $312K, operating cash flow −$1.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Emrosi | $8.1M | $2.8M | $5.3M | +189% |
| Qbrexza | $5.1M | $6.9M | −$1.8M | -26% |
| Accutane | $3.4M | $3.4M | −$37K | -1% |
| Foam franchise products (Amzeeq & Zilxi) | $941K | $1.1M | −$194K | -17% |
| Other / legacy | $232K | $735K | −$503K | -68% |
| Revenue | $18.5M | $15.0M | $3.5M | +23% |
| Net loss | $312K | $3.8M | −$3.5M | -92% |
| Costs & expenses | $18.8M | $18.8M | $17K | +0.1% |
| Operating costs | $18.1M | $17.9M | $169K | +0.9% |
| Interest & other, net | $753K | $860K | −$107K | -12% |
| Income tax | $15K | $60K | −$45K | -75% |
| Cost of revenue | $6.1M | $4.9M | $1.2M | +24% |
| SG&A | $10.9M | $11.9M | −$994K | -8% |
| Other operating costs | $969K | $1.1M | −$95K | -9% |
| Operating cash sources | $3.2M | $2.3M | $893K | +39% |
| Share-based compensation | $1.4M | $1.3M | $101K | +8% |
| Cash used in operations | $1.7M | $942K | $792K | +84% |
| Net loss absorbed | $312K | $3.8M | −$3.5M | -92% |
| Working capital & other | $2.9M | −$1.5M | $4.4M | — |
Questions
How much did Journey Medical's revenue grow year over year in Q2 2026?
Journey Medical's revenue rose $3.5M (+23%) from $15.0M in Q2 2025 to $18.5M in Q2 2026.
What drove Journey Medical's revenue change in Q2 2026?
Emrosi +$5.3M (+189%); Qbrexza −$1.8M (-26%); Other / legacy −$503K (-68%).